ElevateBio Announces Margo Roberts, Ph.D. Joined as Scientific Advisor for Expansion of Company’s Immunotherapy Platform
Receive instant alerts for news on your actions. Claim your 1-week free trial for StreetInsider Premium here.
Dr Roberts brings three decades of expertise to further extend ElevateBio’s leadership in immunotherapy across its protein, viral and cellular engineering technology platforms
CAMBRIDGE, Mass .– (BUSINESS WIRE) – ElevateBio, a cell and gene therapy technology company focused on transformative cell and gene therapies, today announced that Margo Roberts, Ph.D., has joined the company in as a strategic scientific advisor. Dr. Roberts will bring his cutting-edge immunology research, drug discovery and development expertise to the company as it builds a comprehensive immunotherapy platform on behalf of its portfolio companies and strategic partners .
This press release features multimedia. See the full version here: https://www.businesswire.com/news/home/202106110005633/en/
(Photo: Business Wire)
“As one of the leading pioneers who established the field of CAR-T cell research, Margo brings unparalleled depth of cellular immunotherapy science and drug development experience that will prove invaluable to ElevateBio as we set our ambitions on creating powerful cells and genes in patient therapies, ”said Mitchell Finer, Ph.D., Scientific Director of ElevateBio, President of ElevateBio BaseCamp and CEO of LifeEDIT Therapeutics. “We look forward to partnering with Margo in this capacity as she works closely with our R&D teams and portfolio companies who are advancing new cell immunotherapy programs to treat a wide range of diseases with a high unmet need. ”
Dr Roberts has more than three decades of experience in biotechnology and academic immunology and led the early development and application of CAR technology to T cells and stem cells, thus advancing the first clinical trials in CAR cells. T. Most recently, she served as Scientific Director (CSO) of Lyell Immunopharma, Inc., where she oversaw the clinical development of novel CAR and TCR-based cell therapies for solid tumors from discovery to development. the IND. Prior to her position at Lyell, she held the position of CSO at Kite Pharma (acquired by Gilead Sciences), where she built a research organization that was instrumental in the development of Yescarta® CAR-T therapy, and the clinical advancement of CAR / TCR-designed T cell therapies. Following his role as CSO, Dr Roberts served as Senior Vice President of Discovery Research at Kite to focus on developing next-generation therapeutic approaches, including leading Kite’s universal allogeneic T cell programs. Dr Roberts was recently recognized as one of the leading R&D leaders by Terminal news named in the list of 20 women leaders in biopharmacy 2020.
Dr Roberts commented, “It is truly an honor to have the opportunity to bring my experience as a molecular, developmental and experimental biologist to advance ElevateBio’s highly integrated immunotherapy programs. Personally and professionally, I look forward to the opportunity to partner again with my longtime colleague and friend, Mitch Finer, as well as the impressive leadership and research and development teams. and manufacture of ElevateBio as the company takes bold steps to change the face of cell and gene therapy through a multiplatform approach to highly innovative drug development.
Prior to her tenure at Kite, Dr Roberts was Senior Scientist and Director of Immune and Cellular Therapy at Cell Genesys, Inc., where she was at the forefront of CAR T development, taking the first CAR T to trial. clinical studies in humans in 1994. Dr. Roberts was also an Associate Professor at the University of Virginia, is the author of over thirty scientific publications, and is the inventor of thirteen issued US patents and three US patent applications. published. Dr. Roberts received her Bachelor of Science with Honors and Doctorate degrees. degree from the University of Leeds in England.
ElevateBio is a cell and gene therapy technology company designed to fuel the development of transformative cell and gene therapies today and for many decades to come. The company has brought together cutting-edge talent, built world-class facilities and integrated various technological platforms necessary for the rapid innovation and commercialization of cell, gene and regenerative therapies. The company has built an initial technology stack, including gene editing, induced pluripotent stem cells, and protein, viral and cellular engineering. At the center of the business model is ElevateBio BaseCamp, a centralized R&D and manufacturing company that offers manufacturing capabilities of research and development (R&D), process development (PD) and current good manufacturing practices (CGMP). The company is focused on increasing long-term collaborations with industrial partners while continuing to develop its own highly innovative cell and gene therapies. ElevateBio’s team of scientists, drug developers and business builders are redefining what it means to be a tech company in the world of drug development, blurring the line between technology and healthcare.
ElevateBio is headquartered in Cambridge, Mass, with ElevateBio BaseCamp located in Waltham, Mass. For more information, visit us at www.elevate.bio, or follow Elevate on LinkedIn, Twitter, or Instagram.
* As of the date of this press release, SoftBank Group Corp. made capital contributions to enable SoftBank Vision Fund 2 (“SVF 2”) to invest in certain holding companies. The information in this document is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy limited partnership interest in any fund, including SVF 2. SVF 2 does not yet have an external close, and any potential third party investors will receive additional information relating to any SVF 2 investment prior to the close.